The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials
<h4>Background</h4> Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) monotherapy is the standard of care in treating advanced non-small cell lung cancer (NSCLC). Nevertheless, whether adding pemetrexed-based chemotherapy to EGFR-TKI targeted therapy furtherly prolo...
Main Authors: | Bi-Cheng Wang, Wen-Xuan Zhang, Bo-Hua Kuang, Guo-He Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550038/?tool=EBI |
Similar Items
-
The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials.
by: Bi-Cheng Wang, et al.
Published: (2022-01-01) -
Gefitinib plus chemotherapy for EGFR-mutant non-small-cell lung cancer
by: Aman Chaudhary, et al.
Published: (2022-01-01) -
PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
by: A. U. Kulikov
Published: (2015-03-01) -
Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
by: Wang Wen-Ping, et al.
Published: (2012-01-01) -
Correlations of <it>EGFR </it>mutations and increases in <it>EGFR </it>and <it>HER2 </it>copy number to gefitinib response in a retrospective analysis of lung cancer patients
by: English John, et al.
Published: (2007-07-01)